AstraZeneca PLC, which has been criticized for the accuracy of the data, on Wednesday evening published updated phase 3 test data of the coronavirus vaccine, saying it was 76% effective in preventing prevent symptomatic COVID-19.
also reported that their vaccine was 100% effective against severe illness and hospitalizations, and for patients over 65 years of age, it was 85% effective against the virus.
“The highly positive results from the initial analysis of the AZD1222 phase III trial in the United States confirmed the efficacy of the vaccine in line with the pre-ordered interim analysis published on Monday, “The company said in a statement, added that they will submit their data for emergency use licensing to the US Food and Drug Administration in the coming weeks.
On Monday, the UK drug maker said its vaccine had an efficacy rate of 79%. But Monday night, the US National Institute of Allergy and Infectious Diseases said it was concerned that AstraZeneca has released “outdated information”, and the company was charged cherries picking data.
At the time, the company said metrics based on “pre-specified interim analysis” and said it would share the results of “a primary analysis with the most up-to-date performance data” into Thursday.
Earlier on Wednesday, Dr. Anthony Fauci – the head of NIAID – said AstraZeneca’s vaccine was good, even if its effectiveness rate was not as high as initially claimed. “At the end of the day, you know, when you look at the data, this is going to be a good vaccine,” Fauci said during the White House COVID-19 briefing on Wednesday.
“The initial analysis was in line with our previously released interim analysis and confirmed that our COVID-19 vaccine is highly effective in adults,” said AstraZeneca executive director, Mene Pangalos. know in a statement on Wednesday.
The AstraZeneca vaccine is also the subject of concern about blood clotting. But an EU regulator declared last week the drug was “safe and effective”. and in a statement Wednesday night, the company said “The vaccine was well tolerated and no safety concerns related to the vaccine have been identified.”
AstraZeneca’s data comes from a study of 32,000 people.